A wee protein plays a big role in the body’s cancer response. Researchers have been interested in drugs that inhibit the protein Wee1 G2 checkpoint kinase (Wee1) for years, hoping that such compounds could help kill off cancerous cells. But patients taking the drugs in trials were beset with side effects like diarrhea, vomiting, fatigue, and low blood cell counts.
In a new study, researchers now showed that a previously unappreciated function of Wee1 in healthy cells explains these damaging side effects.1 The results, which were published in Nature, could help direct the drugs to patients who could actually benefit.
When Stopping Cancer Cells’ Growth Hurts the Body
Wee1 is a protein that inhibits another protein, cyclin-dependent kinase 1 (CDK1), which moves cells through the cell cycle. This inhibition is especially important in tumor cells where another cell-cycle inhibitor, called TP53, is mutated. These tumor cells replicate rapidly, so rapidly, in fact, that they face incredible molecular stress. Wee1 acts against the body’s best interests by encouraging the cancer cells to take a breather, letting them organize their DNA before moving through the cell cycle. Drugs that inhibit Wee1 essentially cut the brakes of cancer’s runaway car, sending it on an out-of-control journey to cell death.
This observation led to clinical trials of drugs like the Wee1 inhibitor adavosertib. But the drug’s own progress through the clinical trial cycle stalled because of serious side effects. Alexis Barr, a cell biologist at the MRC Laboratory of Medical Sciences and coauthor of the new study, explained in a statement that the team suspected there was a gap in the previous understanding of how Wee1 works.
“Wee1 has been very intensely studied in the later stages of the cell cycle, where targeting its activity for cancer treatment makes sense,” she said. “However, the side effects of Wee1 inhibitors in patients were hard to explain based on these functions so we started to wonder if this Wee1 enzyme had some other function that we hadn't appreciated that could explain these. We wanted to look earlier in the cell cycle to see if there was something we had missed.”
Math Model Reveals Missing Information
The team built a mathematical model to explore how Wee1 inhibition affects earlier cell cycle stages. This model revealed a previously overlooked truth: In non-cancerous cells, a protein degradation complex smashes apart the molecules needed to start replication, preventing replication altogether . When it’s time for cell replication, Wee1 arrives to get rid of this roadblock. By blocking Wee1, inhibitors have been stopping healthy cells from replicating. In areas of the body where rapid cell turnover is essential, like the colon and the blood, this became a major problem. Barr and her colleagues suspect this mechanism may be causing the observed side effects.
The findings don’t mean that drugs like adavosertib have to be scrapped entirely. In some cancers, levels of the protein degradation complex are already reduced, which could make Wee1 inhibitors particularly potent. A lower dose of Wee1 inhibition could potentially produce the best of both worlds—a treatment that targets cancer cells’ vulnerabilities while only producing minimal side effects in healthy tissue.
The work does have another, darker implication. Wee1 inhibitors had been thoroughly tested before clinical trials. Nonetheless, researchers had missed this key role of the drugs. “Now we've uncovered this new function for Wee1, are there other functions that we haven't appreciated? What else is it doing that we have not seen since we've not looked at the right stage?” said Barr.
- Vuillemenot L, et al. WEE1 opposes APC/CCDH1 activity to promote S phase entry. Nature. 2026















